Rating Change
Cantor Fitzgerald analysts reiterated a Neutral rating on Pfizer Inc. (NYSE:PFE) on July 06, 2026.
Rating Change Cantor Fitzgerald analysts reiterated a Neutral rating on Pfizer Inc. (NYSE:PFE) on July 06, 2026. Market Context Pfizer Inc.

Cantor Fitzgerald analysts reiterated a Neutral rating on Pfizer Inc. (NYSE:PFE) on July 06, 2026.
Pfizer Inc. operates in the Healthcare sector. The stock currently trades at $23.72 with a market capitalization of $146.7B. The stock has declined 3.6% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pfizer Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 2 Buy, 7 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 06, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Jul 06, 2026 | HSBC | Hold | N/A |
| Jun 10, 2026 | RBC Capital | Sector Perform | N/A |
| Apr 29, 2026 | Citigroup | Neutral | N/A |
| Apr 20, 2026 | RBC Capital | Underperform | N/A |
Related Tools: Analyst Ratings Dashboard | View PFE Stock Page
A Neutral rating from Cantor Fitzgerald reflects the analyst's outlook on Pfizer Inc. (NYSE:PFE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PFE forecast page.
Current market data
NYSE · PFE
$27.96
Down: -$0.06 · -0.21%
Live quote updated
Keep reading